A double-blind, randomized-withdrawal, placebo-controlled study to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care for the treatment of refractory antibody mediated rejection in adult renal transplant recipients

Trial Profile

A double-blind, randomized-withdrawal, placebo-controlled study to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care for the treatment of refractory antibody mediated rejection in adult renal transplant recipients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Complement C1 inhibitor protein (Primary) ; Complement C1 inhibitor protein (Primary)
  • Indications Transplant rejection
  • Focus Therapeutic Use
  • Sponsors CSL Behring
  • Most Recent Events

    • 07 Sep 2017 Planned End Date changed from 1 Jul 2020 to 16 Oct 2023.
    • 07 Sep 2017 Planned primary completion date changed from 1 Dec 2020 to 16 Jul 2020.
    • 07 Aug 2017 Planned End Date changed from 1 Jun 2023 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top